{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:56Z","timestamp":1792157756211,"version":"4.4.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Steatotic liver disease (SLD) is a new overarching term to replace the term fatty liver disease, which includes metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), and alcohol-related liver disease (ALD). We aimed to examine the association of MASLD, MetALD, and ALD with cancer incidence, and the role of inflammation indicators in mediating these associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Our analysis included 432\u00a0166 participants free of cancer from the UK Biobank. MASLD, MetALD, and ALD were defined based on the nomenclature definitions. Cancer diagnoses were ascertained through linkage to hospitalization and death registration systems. Cox models were fitted to estimate the hazard ratios (HRs), adjusting for potential confounders. Causal mediation analysis was used to explore the mediating role of inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>48\u00a0739 incident cancers occurred over a median follow-up of 13.1\u00a0years. Compared to those without SLD, a higher risk of all cancer was observed in participants with MASLD (HR\u00a0=\u00a01.13, 95% CI\u00a0=\u00a01.11\u20131.16), MetALD (HR\u00a0=\u00a01.07, 95% CI\u00a0=\u00a01.04\u20131.11), or ALD (HR\u00a0=\u00a01.22, 95% CI\u00a0=\u00a01.15\u20131.29). MASLD, MetALD, and ALD were positively associated with obesity-related cancers, and esophageal, stomach, colorectal, liver, biliary tract, pancreatic, postmenopausal breast, uterine, kidney, and bladder cancers (HRs: 1.18\u00a0~\u00a04.97). Inflammation partially mediated the observed association of MASLD and cancer risk by 11.2% to 31.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Individuals with MASLD, MetALD, or ALD are at increased risk of all cancer, and inflammation mediates the effect of MASLD. These findings highlight the importance of cancer screening and prevention in patients with MASLD or MetALD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004181","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:00:29Z","timestamp":1764856829000},"page":"6872-6881","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The mediating role of inflammation in cancer risk among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study"],"prefix":"10.1097","volume":"112","author":[{"given":"Jianhua","family":"Bu","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China"},{"name":"Department of Dermatology, Gansu Provincial Hospital, Lanzhou, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Mi","sequence":"additional","affiliation":[{"name":"Scientific Research Center, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Liang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xie","sequence":"additional","affiliation":[{"name":"Scientific Research Center, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changrui","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yang","sequence":"additional","affiliation":[{"name":"Scientific Research Center, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xia","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, The Seventh Affiliated Hospital, Sun Yat-sen University, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijian","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangsheng","family":"He","sequence":"additional","affiliation":[{"name":"Scientific Research Center, Center for Digestive Disease, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"},{"name":"Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"R1-20260417","doi-asserted-by":"crossref","first-page":"1335\u201347","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R2-20260417","doi-asserted-by":"crossref","first-page":"1138\u201353","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"R3-20260417","first-page":"177\u201389","article-title":"Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease","volume":"292","author":"Hagstr\u00f6m","year":"2022","journal-title":"J Intern Med"},{"key":"R4-20260417","doi-asserted-by":"crossref","first-page":"2212\u201324","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"R5-20260417","doi-asserted-by":"crossref","first-page":"903\u201313","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R6-20260417","doi-asserted-by":"crossref","first-page":"60\u201378","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R7-20260417","doi-asserted-by":"crossref","first-page":"1542\u201356","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"R8-20260417","first-page":"202\u201309","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R9-20260417","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"R10-20260417","doi-asserted-by":"crossref","first-page":"1229\u201336","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"R11-20260417","doi-asserted-by":"crossref","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"R12-20260417","doi-asserted-by":"crossref","first-page":"121\u201335","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"R13-20260417","doi-asserted-by":"crossref","first-page":"e23466","DOI":"10.1096\/fj.202302447R","article-title":"Oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD): how does the animal model resemble human disease?","volume":"38","author":"Jakubek","year":"2024","journal-title":"FASEB J"},{"key":"R14-20260417","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R15-20260417","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R16-20260417","first-page":"1388\u2013402","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R17-20260417","doi-asserted-by":"crossref","first-page":"794\u201398","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-20260417","doi-asserted-by":"crossref","first-page":"1461\u201365","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nature Genet"},{"key":"R19-20260417","doi-asserted-by":"crossref","first-page":"1209\u201317","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"R20-20260417","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-20260417","first-page":"137\u201350","article-title":"Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros","volume":"18","author":"Valeri","year":"2013","journal-title":"Psychol Methods"},{"key":"R22-20260417","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/EDE.0000000000000253","article-title":"SAS macro for causal mediation analysis with survival data","volume":"26","author":"Valeri","year":"2015","journal-title":"Epidemiology"},{"key":"R23-20260417","doi-asserted-by":"crossref","first-page":"691\u2013702","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"R24-20260417","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.jhep.2023.11.016","article-title":"Suboptimal hydration status increases the risk of incident MASLD: a pediatric cohort study","volume":"80","author":"Li","year":"2024","journal-title":"J Hepatol"},{"key":"R25-20260417","first-page":"218\u201328","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R26-20260417","doi-asserted-by":"crossref","first-page":"820\u201328","DOI":"10.1111\/liv.15195","article-title":"Risk of hepatic and extrahepatic cancer in NAFLD: a population-based cohort study","volume":"42","author":"Bj\u00f6rkstr\u00f6m","year":"2022","journal-title":"Liver Int"},{"key":"R27-20260417","doi-asserted-by":"crossref","first-page":"985858","DOI":"10.3389\/fendo.2023.985858","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R28-20260417","first-page":"778\u201388","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"R29-20260417","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/biomedicines11030690","article-title":"Estrogens in adipose tissue physiology and obesity-related dysfunction","volume":"11","author":"Kury\u0142owicz","year":"2023","journal-title":"Biomedicines"},{"key":"R30-20260417","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12964-024-01583-0","article-title":"Endogenous estrogen metabolites as oxidative stress mediators and endometrial cancer biomarkers","volume":"22","author":"Bukato","year":"2024","journal-title":"Cell Commun Signal"},{"key":"R31-20260417","doi-asserted-by":"crossref","first-page":"553\u201358","DOI":"10.1093\/mutage\/gew016","article-title":"Increased levels of the acetaldehyde-derived DNA adduct N 2 -ethyldeoxyguanosine in oral mucosa DNA from Rhesus monkeys exposed to alcohol","volume":"31","author":"Balbo","year":"2016","journal-title":"Mutagenesis"},{"key":"R32-20260417","doi-asserted-by":"crossref","first-page":"800\u201309","DOI":"10.1002\/hep.24097","article-title":"Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease","volume":"53","author":"Ayonrinde","year":"2011","journal-title":"Hepatology"},{"key":"R33-20260417","doi-asserted-by":"crossref","first-page":"2621\u201337","DOI":"10.1172\/JCI31021","article-title":"Obesity-associated improvements in metabolic profile through expansion of adipose tissue","volume":"117","author":"Kim","year":"2007","journal-title":"J Clin Investig"},{"key":"R34-20260417","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.03.02","article-title":"Smoking, immunity, and DNA damage","volume":"8","author":"Yamaguchi","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R35-20260417","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","article-title":"Trends in insulin resistance: insights into mechanisms and therapeutic strategy","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct and Targeted Therapy"},{"key":"R36-20260417","doi-asserted-by":"crossref","first-page":"1056\u201360","DOI":"10.1007\/s00125-009-1285-z","article-title":"A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans","volume":"52","author":"Kotronen","year":"2009","journal-title":"Diabetologia"},{"key":"R37-20260417","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1182\/blood-2018-99-120356","article-title":"The association between circulating inflammatory markers and metabolic syndrome: a general population study","volume":"132","author":"Pedersen","year":"2018","journal-title":"Blood"},{"key":"R38-20260417","doi-asserted-by":"crossref","first-page":"2217\u201324","DOI":"10.1200\/JCO.2008.19.8440","article-title":"Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer","volume":"27","author":"Allin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R39-20260417","doi-asserted-by":"crossref","first-page":"3272\u201379","DOI":"10.1002\/cncr.28185","article-title":"The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate","volume":"119","author":"Hall","year":"2013","journal-title":"Cancer"},{"key":"R40-20260417","article-title":"Inflammatory markers in cancer immunotherapy","volume":"10","author":"Ravindranathan","year":"2021","journal-title":"Biology (Basel)"},{"key":"R41-20260417","doi-asserted-by":"crossref","first-page":"57\u201376","DOI":"10.1111\/nyas.12416","article-title":"Obesity and cancer pathogenesis","volume":"1311","author":"Berger","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"R42-20260417","doi-asserted-by":"crossref","first-page":"998\u20131027","DOI":"10.3390\/curroncol31020075","article-title":"Insulin resistance: the increased risk of cancers","volume":"31","author":"Szablewski","year":"2024","journal-title":"Curr Oncol"},{"key":"R43-20260417","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10565-025-10025-7","article-title":"Lipotoxicity, lipid peroxidation and ferroptosis: a dilemma in cancer therapy","volume":"41","author":"Ma","year":"2025","journal-title":"Cell Biol Toxicol"},{"key":"R44-20260417","doi-asserted-by":"crossref","first-page":"799\u2013812","DOI":"10.4093\/dmj.2021.0077","article-title":"Obesity, diabetes, and increased cancer progression","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"R45-20260417","first-page":"1\u201317","article-title":"Gut microbiota as a metabolic mediator to prevent or attenuate MASLD","author":"Luo","year":"2025","journal-title":"Crit Rev Food Sci Nutr"},{"key":"R46-20260417","first-page":"815\u201326","article-title":"Mechanism of metabolic dysfunction-associated steatotic liver disease: important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"R47-20260417","doi-asserted-by":"crossref","first-page":"154874","DOI":"10.1016\/j.metabol.2021.154874","article-title":"Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes","volume":"124","author":"Li","year":"2021","journal-title":"Metabolism"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:04:29Z","timestamp":1776423869000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004181","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-06-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}